• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

移植医护人员在后预防时期巨细胞病毒管理策略的调查。

Survey of Post-Prophylaxis Delayed-Onset Cytomegalovirus Management Strategies Among Transplant Providers.

机构信息

Division of Infectious Diseases, Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.

Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.

出版信息

Clin Transplant. 2024 Nov;38(11):e70015. doi: 10.1111/ctr.70015.

DOI:10.1111/ctr.70015
PMID:39476330
Abstract

BACKGROUND

Preventive strategies for cytomegalovirus (CMV) in the posttransplant period have changed the pattern of CMV infections, now more commonly manifesting as late-onset occurrences known as post-prophylaxis delayed-onset CMV disease (PPDOC). We conducted a survey to investigate provider practices in managing PPDOC.

METHODS

A web-based provider survey on the management of PPDOC was developed using Research Electronic Data Capture (REDCap). It was distributed to the online forums of the American Society of Transplantation communities of practice (COP) for Infectious Diseases (IDCOP), Kidney and Pancreas (KPCOP), Liver and Intestinal (LICOP), and Thoracic and Critical Care (TCCOP). The survey was posted twice within a span of a month.

RESULTS

Fifty-six respondents, comprising 50 (89%) transplant physicians and 6 (11%) transplant pharmacists, from 46 distinct transplant centers, completed the survey. Universal antiviral prophylaxis (UAP) was the predominant preventive approach for both high-risk (85%) and moderate-risk (85%) transplant recipients. Out of 56, 51 respondents completed the questions regarding management of PPDOC. Regular surveillance with nucleic acid amplification tests (NAAT) (88%) was the most commonly used approach in high-risk recipients, while symptom monitoring (73%) was the most common strategy in moderate-risk recipients. Immunologic monitoring was used only by a few respondents who found it moderately useful in high-risk recipients.

CONCLUSION

Management of PPDOC was highly variable among providers and strategies differed based on patient risk profile. These findings could help shape future studies and guidelines to harmonize CMV management.

摘要

背景

移植后时期针对巨细胞病毒 (CMV) 的预防策略改变了 CMV 感染的模式,现在更常见的是表现为后期发病,称为预防后延迟发生的 CMV 疾病 (PPDOC)。我们进行了一项调查,以了解提供者在管理 PPDOC 方面的实践情况。

方法

使用 Research Electronic Data Capture (REDCap) 开发了一项关于 PPDOC 管理的基于网络的提供者调查。它分发给美国移植协会传染病实践社区 (IDCOP)、肾脏和胰腺 (KPCOP)、肝脏和肠道 (LICOP) 和胸科和重症监护 (TCCOP) 的在线论坛。该调查在一个月的时间内发布了两次。

结果

56 名受访者来自 46 个不同的移植中心,其中包括 50 名(89%)移植医生和 6 名(11%)移植药剂师,完成了调查。普遍抗病毒预防 (UAP) 是高风险(85%)和中风险(85%)移植受者的主要预防方法。在 56 名受访者中,有 51 名回答了有关 PPDOC 管理的问题。定期进行核酸扩增检测 (NAAT)(88%)是高风险受者中最常用的方法,而症状监测(73%)是中风险受者中最常见的策略。免疫监测仅被少数认为在高风险受者中具有中等价值的受访者使用。

结论

提供者在管理 PPDOC 方面的做法差异很大,策略根据患者的风险状况而有所不同。这些发现可以帮助制定未来的研究和指南,以协调 CMV 的管理。

相似文献

1
Survey of Post-Prophylaxis Delayed-Onset Cytomegalovirus Management Strategies Among Transplant Providers.移植医护人员在后预防时期巨细胞病毒管理策略的调查。
Clin Transplant. 2024 Nov;38(11):e70015. doi: 10.1111/ctr.70015.
2
Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey.分子诊断时代欧洲各中心实体器官移植受者巨细胞病毒感染的管理:一项欧洲移植感染和临床微生物学会调查
Transpl Infect Dis. 2017 Dec;19(6). doi: 10.1111/tid.12773. Epub 2017 Oct 25.
3
Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.抢先治疗与抗病毒预防对供体血清阳性受者血清阴性肝移植患者巨细胞病毒病的影响:一项随机临床试验。
JAMA. 2020 Apr 14;323(14):1378-1387. doi: 10.1001/jama.2020.3138.
4
Cytomegalovirus infection post-pancreas-kidney transplantation--results of antiviral prophylaxis in high-risk patients.巨细胞病毒感染胰腺-肾移植术后——高危患者抗病毒预防的结果。
Clin Transplant. 2013 Jul-Aug;27(4):503-9. doi: 10.1111/ctr.12138. Epub 2013 Jun 3.
5
Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage.在一个接受医疗保险D部分覆盖的大型肾移植受者回顾性队列中进行巨细胞病毒预防的药物流行病学研究。
Clin Transplant. 2016 Apr;30(4):435-44. doi: 10.1111/ctr.12706. Epub 2016 Mar 4.
6
Real-life use of letermovir prophylaxis for cytomegalovirus in heart transplant recipients.心脏移植受者更昔洛韦预防巨细胞病毒的实际应用。
Clin Transplant. 2024 May;38(5):e15327. doi: 10.1111/ctr.15327.
7
Cytomegalovirus Post-Prophylaxis Surveillance in High-Risk Kidney and Liver Recipients Prevents CMV End-Organ Disease and Ganciclovir-Resistance.巨细胞病毒预防治疗后监测可预防高危肾和肝移植受者的巨细胞病毒终末器官疾病和更昔洛韦耐药。
Clin Transplant. 2024 Sep;38(9):e15453. doi: 10.1111/ctr.15453.
8
New developments in the management of cytomegalovirus infection after solid organ transplantation.实体器官移植后巨细胞病毒感染管理的新进展。
Drugs. 2010 May 28;70(8):965-81. doi: 10.2165/10898540-000000000-00000.
9
Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.重新评估巨细胞病毒感染在肾移植和肾胰联合移植中的影响。
Am J Kidney Dis. 2002 May;39(5):1088-95. doi: 10.1053/ajkd.2002.32793.
10
Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.接受抗胸腺细胞球蛋白诱导治疗的血清学阳性肾移植受者的巨细胞病毒预防:晚期巨细胞病毒疾病的结局和危险因素。
Transpl Infect Dis. 2018 Oct;20(5):e12929. doi: 10.1111/tid.12929. Epub 2018 Jul 2.

引用本文的文献

1
The Fourth International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation.《实体器官移植中巨细胞病毒管理的第四届国际共识指南》
Transplantation. 2025 Jul 1;109(7):1066-1110. doi: 10.1097/TP.0000000000005374. Epub 2025 Apr 9.